10x Genomics (TXG) Fundamental Analysis: Revenue, Earnings & Valuation

0.33 / 10

Underperform

Fundamentally the stock is rated Underperform with a 0.3/10 strength. Profit‑MV and profit margins are negative, while cash‑flow‑to‑revenue and cash‑flow‑to‑liabilities ratios are strong, yielding modest quality scores but overall weak fundamentals.

Analysis Checks(6/10)

Revenue-MV

Value-0.43

Score1/3

Weight65.71%

1M Return-2.72%

Net cash flow from operating activities / Operating revenue (%)

Value21.16

Score3/3

Weight-47.86%

1M Return1.62%

Profit-MV

Value0.66

Score1/3

Weight74.49%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight66.68%

1M Return-2.58%

Net profit margin (%)

Value-6.77

Score2/3

Weight-18.05%

1M Return0.68%

Cash-UP

Value-0.33

Score1/3

Weight145.62%

1M Return-6.49%

Net cash flow from operating activities / Total liabilities (%)

Value0.56

Score2/3

Weight-20.21%

1M Return0.68%

EBIT / Total operating revenue (%)

Value-9.33

Score2/3

Weight-25.93%

1M Return1.01%

Asset-MV

Value-0.55

Score3/3

Weight-122.38%

1M Return3.88%

Net profit / Total operating revenue (%)

Value-6.77

Score2/3

Weight-18.05%

1M Return0.68%

Is TXG undervalued or overvalued?

TXG scores 0.33/10 on fundamentals and holds a Premium valuation at present. Backed by its -5.78% ROE, -6.77% net margin, -65.51 P/E ratio, 3.58 P/B ratio, and 76.97% earnings growth, these metrics solidify its Underperform investment rating.